Aethlon Medical, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2020 (filed June 25, 2020). Although the request identifies 2019 Q4, this filing reports the full fiscal year, with 2019 comparatives; it does not provide standalone fourth-quarter results.
Business context and development
Aethlon is a clinical-stage medical technology company. Its Hemopurifier is designed to remove tumor-derived exosomes and certain viruses from blood. The company also consolidates its 80%-owned subsidiary, Exosome Sciences, Inc. (ESI), which develops exosome-based biomarkers. The company had no commercial product sales; all reported revenue came from National Institutes of Health (NIH) contracts and grants.
- The FDA had granted Hemopurifier Breakthrough Device designation for advanced or metastatic cancer and for life-threatening viruses without approved therapies. Designation is not FDA marketing approval.
- An FDA-approved early-feasibility cancer study with pembrolizumab was in startup at UPMC Hillman Cancer Center; it planned to enroll 10–12 subjects. The filing describes planned study endpoints, not results.
- After year-end, on June 17, 2020, the FDA approved an IDE supplement for a planned COVID-19 feasibility study of up to 40 patients at up to 20 U.S. centers.
Financial results and liquidity
| Metric | FY 2020 | FY 2019 |
|---|---|---|
| Revenue | $650,187 | $229,625 |
| Operating expenses | $6,580,175 | $6,228,642 |
| Operating loss | $(5,929,988) | $(5,999,017) |
| Net loss attributable to common stockholders | $(6,373,948) | $(6,194,719) |
| Basic and diluted loss per share | $(1.87) | $(5.13) |
| Net cash used in operating activities | $(5,197,608) | $(4,293,433) |
- Revenue increased by $420,562, largely because the new Phase II melanoma contract contributed $620,187; the completed Phase I melanoma contract and lower breast-cancer grant revenue partly offset the increase. Revenue remained far below operating costs.
- Operating expenses rose $351,533. Higher professional fees and general and administrative costs were partly offset by lower payroll and related expenses. Net loss increased $179,229, including a $447,011 debt-extinguishment loss.
- Cash at March 31, 2020 was $9,604,780, versus $3,828,074 a year earlier; working capital was $8,973,393, versus $2,214,230. The company stated that March 31 cash was expected to fund operations for at least 12 months from the filing date.
- Total assets were $10,387,686 and total liabilities $1,110,260 at March 31, 2020. Convertible notes were paid off in July 2019; none remained at year-end. Cash flow from financing was $11,125,979, principally from equity offerings and warrant exercises.
- There was no meaningful commercial gross margin to assess because revenue consisted entirely of government contract and grant revenue. ESI had no revenue.
Material changes, outlook and risks
- Funding during FY 2020 included net proceeds of $4,091,437 from the December 2019 public offering, $3,364,878 from the January 2020 registered direct offering/private placement, $896,031 from at-the-market sales, and $3,807,162 from warrant exercises. These financings materially increased cash and outstanding shares.
- After year-end, the company raised a further $7,260,869 net through its ATM facility in June 2020, selling 2,685,600 shares. This subsequent financing is not included in March 31 balances.
- Management provided no revenue or earnings guidance. It expects continued losses and states that additional financing will be needed to meet longer-term development objectives. The stated 12-month cash runway is management’s estimate, not assurance of future funding or profitability.
- COVID-19 created uncertainty around clinical enrollment, site startup, supply chains, operations, capital access and timing. The company reported no significant disruption to date but could not estimate future effects.
- Other key risks include dependence on NIH funding, clinical and regulatory failure or delay, limited suppliers for critical device components, competition, potential dilution from future financings, and limited commercialization capabilities. The device remained investigational and the company expected a demanding FDA approval process.
- The SEC temporarily suspended trading in Aethlon stock for 10 days beginning February 7, 2020, citing concerns about marketplace information disseminated by third-party promoters and unusual market activity. The company said it could not predict the investigation’s outcome or impact.
- The company reported disclosure controls and internal control over financial reporting effective as of March 31, 2020. The independent auditor audited the financial statements but was not engaged to audit internal control effectiveness.
Important facts for investors to verify
- Whether the cancer and COVID-19 feasibility studies started, enrolled patients and produced safety or efficacy data; distinguish clinical evidence from company expectations and preclinical results.
- Cash burn, runway assumptions, subsequent financing needs and the effect of post-year-end share issuance and outstanding warrants on dilution.
- Progress and remaining milestones under the $1.86 million Phase II NCI contract, and the status of the breast-cancer grant and its deferred revenue.
- Any developments in the SEC investigation, Nasdaq listing compliance and the effect of trading volatility on the company’s ability to raise capital.
- Whether critical suppliers, manufacturing capacity and COVID-19-related clinical-site constraints affect timelines or device availability.